{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:11:19Z","timestamp":1791267079966,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>\n                           <jats:italic>Summary<\/jats:italic>\n                        <\/jats:title>\n                <jats:p>In a characterization of treatment rates and healthcare costs among patients with an osteoporotic-related fragility fracture overall and by site of care, costs were high and treatment rates were low.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Osteoporotic fractures can be debilitating, even fatal, among older adults. The cost of osteoporosis and related fractures is projected to increase to more than $25 billion by 2025. The objective of this analysis is to characterize disease-related treatment rates and healthcare costs of patients with an osteoporotic fragility fracture overall and by site of fracture diagnosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this retrospective analysis, individuals with fragility fractures were identified in the Merative MarketScan\u00ae Commercial and Medicare Databases among women 50\u00a0years of age or older and diagnosed with fragility fracture between 1\/1\/2013 and 6\/30\/2018 (earliest fracture diagnosis\u2009=\u2009index). Cohorts were categorized by clinical site of care where the diagnosis of fragility fracture was made and were continuously followed for 12\u00a0months prior to and following index. Sites of care were inpatient admission, outpatient office, outpatient hospital, emergency room hospital, and urgent care.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 108,965 eligible patients with fragility fracture (mean age 68.8), most were diagnosed during an inpatient admission or outpatient office visit (42.7%, 31.9%). The mean annual healthcare costs among patients with fragility fracture were $44,311 (\u00b1\u2009$67,427) and were highest for those diagnosed in an inpatient setting ($71,561\u2009\u00b1\u2009$84,072). Compared with other sites of care at fracture diagnosis, patients diagnosed during an inpatient admission also had highest proportion of subsequent fractures (33.2%), osteoporosis diagnosis (27.7%), and osteoporosis therapy (17.2%) during follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The site of care for diagnosis of fragility fracture affects treatment rates and healthcare costs. Further studies are needed to determine how attitude or knowledge about osteoporosis treatment or healthcare experiences differ at various clinical sites of care in the medical management of osteoporosis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11657-023-01229-7","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T21:48:15Z","timestamp":1679867295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Treatment rates and healthcare costs of patients with fragility fracture by site of care: a real-world data analysis"],"prefix":"10.1007","volume":"18","author":[{"given":"A.","family":"Singer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. R.","family":"McClung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. D.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Yehoshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"key":"1229_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jsbmb.2013.09.008","volume":"142","author":"SH Tella","year":"2014","unstructured":"Tella SH, Gallagher JC (2014) Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol 142:155\u2013170","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"9319","key":"1229_CR2","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","volume":"359","author":"SR Cummings","year":"2002","unstructured":"Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. The Lancet 359(9319):1761\u20131767","journal-title":"The Lancet"},{"key":"1229_CR3","unstructured":"International Osteoporosis Foundation (2018) Broken bones, broken lives: a roadmap to solve the fragility fracture crisis in Europe. 2018; https:\/\/www.osteoporosis.foundation\/educational-hub\/files\/broken-bones-broken-lives-roadmap-solve-fragility-fracture-crisis-europe."},{"issue":"12","key":"1229_CR4","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s00198-008-0634-y","volume":"19","author":"JA Cauley","year":"2008","unstructured":"Cauley JA, Wampler NS, Barnhart JM et al (2008) Incidence of fractures compared to cardiovascular disease and breast cancer: the Women\u2019s Health Initiative Observational Study. Osteoporos Int 19(12):1717\u20131723","journal-title":"Osteoporos Int"},{"key":"1229_CR5","unstructured":"Bone Health & Osteoporosis Foundation (2022) What is osteoporosis and what causes it?; https:\/\/www.bonehealthandosteoporosis.org\/patients\/what-is-osteoporosis\/."},{"key":"1229_CR6","doi-asserted-by":"crossref","unstructured":"Singer A, Exuzides A, Spangler L, et al (2015) Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Paper presented at: Mayo Clinic Proceedings","DOI":"10.1016\/j.mayocp.2014.09.011"},{"issue":"6","key":"1229_CR7","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s00198-010-1419-7","volume":"22","author":"SW Blume","year":"2011","unstructured":"Blume SW, Curtis JR (2011) Medical costs of osteoporosis in the elderly Medicare population. Osteoporos Int 22(6):1835\u20131844","journal-title":"Osteoporos Int"},{"issue":"9","key":"1229_CR8","doi-asserted-by":"publisher","first-page":"e10192","DOI":"10.1002\/jbm4.10192","volume":"3","author":"EM Lewiecki","year":"2019","unstructured":"Lewiecki EM, Ortendahl JD, Vanderpuye-Orgle J et al (2019) Healthcare policy changes in osteoporosis can improve outcomes and reduce costs in the United States. JBMR plus 3(9):e10192","journal-title":"JBMR plus"},{"issue":"8","key":"1229_CR9","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s00198-018-4559-9","volume":"29","author":"M Gupta","year":"2018","unstructured":"Gupta M, Shah S, Peterson S, Baim S (2018) Rush Fracture Liaison Service for capturing \u201cmissed opportunities\u201d to treat osteoporosis in patients with fragility fractures. Osteoporos Int 29(8):1861\u20131874","journal-title":"Osteoporos Int"},{"issue":"5","key":"1229_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/MAJ.0000000000000562","volume":"350","author":"EA Aguilar","year":"2015","unstructured":"Aguilar EA, Barry SD, Cefalu CA et al (2015) Osteoporosis diagnosis and management in long-term care facility. Am J Med Sci 350(5):357\u2013363","journal-title":"Am J Med Sci"},{"issue":"1","key":"1229_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jamda.2020.11.019","volume":"22","author":"JD Niznik","year":"2021","unstructured":"Niznik JD, Li X, Gilliam MA et al (2021) Are nursing home residents with dementia appropriately treated for fracture prevention? J Am Med Dir Assoc. 22(1):28-35 e23","journal-title":"J Am Med Dir Assoc."},{"issue":"12","key":"1229_CR12","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1007\/s00198-013-2364-z","volume":"24","author":"M Hiligsmann","year":"2013","unstructured":"Hiligsmann M, Salas M, Hughes DA et al (2013) Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. Osteoporos Int 24(12):2907\u20132918","journal-title":"Osteoporos Int"},{"issue":"4","key":"1229_CR13","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/BOR.0b013e32832c6aa4","volume":"21","author":"AH Warriner","year":"2009","unstructured":"Warriner AH, Curtis JR (2009) Adherence to osteoporosis treatments: room for improvement. Curr Opin Rheumatol 21(4):356","journal-title":"Curr Opin Rheumatol"},{"key":"1229_CR14","unstructured":"National Instites of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases (2019) For people with osteoporosis: how to find a doctor. 2019; https:\/\/www.bones.nih.gov\/health-info\/bone\/osteoporosis\/find-doctor"},{"issue":"11","key":"1229_CR15","doi-asserted-by":"publisher","first-page":"818","DOI":"10.7326\/M15-1361","volume":"166","author":"A Qaseem","year":"2017","unstructured":"Qaseem A, Forciea M, McLean RM, Denberg TD, for the Clinical Guidelines Committee of the American College of P (2017) Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Internal Med 166(11):818\u2013839","journal-title":"Ann Internal Med"},{"issue":"4","key":"1229_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.eprac.2021.02.001","volume":"27","author":"NB Watts","year":"2021","unstructured":"Watts NB, Camacho PM, Lewiecki EM, Petak SM (2021) American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocrine Practice\u202f: Off J Am College Endocrinol Am Assoc Clin Endocrinol 27(4):379\u2013380","journal-title":"Endocrine Practice : Off J Am College Endocrinol Am Assoc Clin Endocrinol"},{"issue":"6","key":"1229_CR17","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613\u2013619","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"1229_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11657-016-0280-5","volume":"11","author":"M Bonafede","year":"2016","unstructured":"Bonafede M, Shi N, Barron R, Li X, Crittenden D, Chandler D (2016) Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data. Arch Osteoporos 11(1):1\u20137","journal-title":"Arch Osteoporos"},{"issue":"3","key":"1229_CR19","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00198-016-3868-0","volume":"28","author":"H Johansson","year":"2017","unstructured":"Johansson H, Siggeirsd\u00f3ttir K, Harvey NC et al (2017) Imminent risk of fracture after fracture. Osteoporos Int 28(3):775\u2013780","journal-title":"Osteoporos Int"},{"issue":"8","key":"1229_CR20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1302\/2046-3758.118.BJR-2021-0238.R3","volume":"11","author":"N Walter","year":"2022","unstructured":"Walter N, Hierl K, Brochhausen C, Alt V, Rupp M (2022) The epidemiology and direct healthcare costs of aseptic nonunions in Germany - a descriptive report. Bone & Joint Res 11(8):541\u2013547","journal-title":"Bone & Joint Res"},{"issue":"9319","key":"1229_CR21","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","volume":"359","author":"SR Cummings","year":"2002","unstructured":"Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359(9319):1761\u20131767","journal-title":"Lancet"},{"issue":"1","key":"1229_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00198-018-4732-1","volume":"30","author":"A Balasubramanian","year":"2019","unstructured":"Balasubramanian A, Zhang J, Chen L et al (2019) Risk of subsequent fracture after prior fracture among older women. Osteoporos Int 30(1):79\u201392","journal-title":"Osteoporos Int"},{"issue":"1","key":"1229_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s11657-020-00784-7","volume":"15","author":"AA Yusuf","year":"2020","unstructured":"Yusuf AA, Hu Y, Chandler D, Crittenden DB, Barron RL (2020) Predictors of imminent risk of fracture in Medicare-enrolled men and women. Arch Osteoporos 15(1):120","journal-title":"Arch Osteoporos"},{"issue":"5","key":"1229_CR24","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/jbmr.3079","volume":"32","author":"CW Gillespie","year":"2017","unstructured":"Gillespie CW, Morin PE (2017) Osteoporosis-related health services utilization following first hip fracture among a cohort of privately-insured women in the United States, 2008\u20132014: an observational study. J Bone Miner Res 32(5):1052\u20131061","journal-title":"J Bone Miner Res"},{"issue":"12","key":"1229_CR25","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1002\/jbmr.2565","volume":"30","author":"S Jha","year":"2015","unstructured":"Jha S, Wang Z, Laucis N, Bhattacharyya T (2015) Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996\u20132012: an ecological analysis. J Bone Miner Res 30(12):2179\u20132187","journal-title":"J Bone Miner Res"},{"issue":"9","key":"1229_CR26","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1002\/jbmr.2202","volume":"29","author":"DH Solomon","year":"2014","unstructured":"Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res. 29(9):1929\u20131937","journal-title":"J Bone Miner Res."},{"issue":"2","key":"1229_CR27","first-page":"319","volume":"35","author":"SM Cadarette","year":"2008","unstructured":"Cadarette SM, Katz JN, Brookhart MA et al (2008) Trends in drug prescribing for osteoporosis after hip fracture, 1995\u20132004. J Rheumatol 35(2):319\u2013326","journal-title":"J Rheumatol"},{"key":"1229_CR28","unstructured":"Bledsoe L, Alessi K, Toro JB, Giordano B, Hanypsiak BT (2018) Fragility fractures: diagnosis and treatment. Am J Ortho (Belle Mead, NJ). 47(12)"},{"key":"1229_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-2474-5-11","volume":"5","author":"A Papaioannou","year":"2004","unstructured":"Papaioannou A, Giangregorio L, Kvern B, Boulos P, Ioannidis G, Adachi JD (2004) The osteoporosis care gap in Canada. BMC Musculoskelet Disord 5:11","journal-title":"BMC Musculoskelet Disord"},{"issue":"2","key":"1229_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00774-018-0923-2","volume":"37","author":"S Bougioukli","year":"2019","unstructured":"Bougioukli S, \u039aollia P, Koromila T et al (2019) Failure in diagnosis and under-treatment of osteoporosis in elderly patients with fragility fractures. J Bone Miner Metab 37(2):327\u2013335","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"1229_CR31","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00198-020-05557-z","volume":"32","author":"E McCloskey","year":"2021","unstructured":"McCloskey E, Rathi J, Heijmans S et al (2021) The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study. Osteoporos Int 32(2):251\u2013259","journal-title":"Osteoporos Int"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-023-01229-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-023-01229-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-023-01229-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T13:27:03Z","timestamp":1704374823000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-023-01229-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1229"],"URL":"https:\/\/doi.org\/10.1007\/s11657-023-01229-7","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,11]]},"assertion":[{"value":"1 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All database records are statistically de-identified and certified to be fully compliant with US patient confidentiality requirements set forth in the Health Insurance Portability and Accountability Act of 1996. Because this study used only de-identified patient records and did not involve the collection, use, or transmittal of individually identifiable data, this study was exempted from Institutional Review Board approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"\u2022 Michele McDermott declares the following conflict of interest: Dr. McDermott is employed by Amgen Inc.\u2022 Alon Yehoshua declares the following conflict of interest: At the time of manuscript development, Dr. Yehoshua was employed by Amgen Inc.\u2022 Cynthia Morrow declares the following conflict of interest: Dr. Morrow was employed by Merative, formerly IBM Watson Health, which received funding from Amgen Inc. to conduct this study.Oth Tran declares at the time of manuscript development, Mr. Tran was employed by Merative, formerly IBM Watson Health, which received funding from Amgen Inc. to conduct this study.\u2022 Michael McClung declares the following conflict of interest: Dr. McClung receives consulting fees and honorarium from Amgen Inc.\u2022 Andrea Singer declares the following conflict of interest: Dr. Singer receives research funding paid to her institution by Radius Health and UCB. Dr. Singer serves on consulting\/advisory boards for Agnovos, Amgen Inc., Radius Health, and UCB. Dr. Singer is on the Speaker\u2019s Bureau for Amgen Inc. and Radius Health.\u2022 Dr. Goldstein and Dr. Kagan declare they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"42"}}